Processing aids with quality and reliability the industry demands

Italy-based polyurethanes plant at Correggio is latest in a series of independent verifications for circular and bio-circular solutions.

CARBOWAX™ and CARBOWAX™ SENTRY™ Polyethylene Glycols (PEGs) are highly versatile excipients and active pharmaceutical ingredients (APIs) produced to meet the exacting requirements of the pharmaceutical industry

CARBOWAX™ SENTRY™ LPEG and MPEGs are pharmaceutical excipients which can be used in the manufacturing of capsules as hydrophilic fillers for solubilization of the API, but also as plasticizer in the coating of the gelatin capsules.

Enhance topical formulations with CARBOWAX™ SENTRY™ Polyethylene Glycols (PEGs)

Dow offers a range of solvents to address the needs of the highly regulated pharmaceutical industry. With Dow’s global sourcing, all of your manufacturing locations can receive the same high quality product with every order. Please visit our API manufacturing page and click on the brochure to selected products that are manufactured to Current Good Manufacturing Practices (cGMP), and meet additional requirements from the appropriate governing bodies. Industrial grades are also available with impurities disclosed upon request.

Dow fluid specialists can help you design, operate, and maintain your heat transfer system for optimum performance and economy. The family of DOWTHERM™ and SYLTHERM™ heat transfer fluids available from Dow are high performance products. The line includes two distinct fluid chemistries – synthetic organic and silicone. You’ll find an overview description of our full line of synthetic fluids, plus recommended applications on this brochure, including pharmaceutical industry.

Through our Decarbonize & Grow and Transform the Waste strategies, we progressed our sustainability targets. Discover how

To develop safer materials that meet the needs of our customers and the value chain, we monitor regulatory trends and use cutting-edge science.

Dow expands Protect the Climate targets to include climate adaptation benchmarks focused on water and nature.

CARBOWAX™️ SENTRY™️ Polyethylene Glycols (PEGs) are widely used in the consumer health and pharmaceutical industries because of their unique formulation properties, low toxicity, mildness and water-solubility. CARBOWAX™️ SENTRY™️ Methoxypolyethylene Glycols (MPEGs) are primarily used as intermediates in the synthesis of pharmaceutical actives, for example, in esterification reactions. They have also been found to enhance the water solubility of less polar compounds and are used in topical applications.

CARBOWAX™️ SENTRY™️ Polyethylene Glycols (PEGs) 3350 and 4000 Uninhibited are active pharmaceutical ingredients (APIs) produced to address the needs of the most stringent requirements of the pharmaceutical industry. These APIs are well-known in the treatment of chronic constipation. Functioning as an osmotic laxative, they offer a mild and effective treatment while minimizing adverse side effects often seen with other laxative types. These products are also widely used in a formulation as an intestinal lavage to facilitate bowel cleansing prior to medical procedures such as colonoscopies, radiological exams, or gastrointestinal surgery.

CARBOWAX™️ SENTRY™️ Polyethylene Glycols (PEGs), CARBOWAX™️ SENTRY™️ Methoxypolyethylene Glycols (MPEGs), and VERSENE™️ NA Edetate Disodium are among the most versatile excipients produced to meet the requirements of the consumer health and pharmaceutical industry. Our products have been successfully used in over-the-counter and pharmaceutical formulations to impart enhanced solvency, lubricity, hygroscopicity, stability and other important functional properties.

There is an increasing preference for skin delivery remedies that can be self-applied at home. Formulators must strive to deliver active ingredients through an exceptional sensory experience to patients of all ages. CARBOWAX™️ SENTRY™️ Polyethylene Glycols (PEGs) have a long history of use in topical applications because they meet all compendial requirements. Connect with our technical team for more information via our CPHI online portal.

This session was originally broadcast as part of the CPHI Worldwide 2021 digital content programme. One of the top priorities of pharmaceutical companies in bringing new products to market is to prove a drug substance is safe and effective against a certain illness. As you would expect, especially in the beginning stages of development, companies primarily focus on the API itself and not necessarily the excipients that will go into the final drug product. Instead, compendial requirements and guidelines such as those from ICH exist to ensure excipient quality and safety. Not only this is important from a regulatory perspective, but excipient quality can also impact product performance, even if those excipients meet all compendial requirements. In this session, you will learn about: Recent regulatory developments relating to residual impurities in pharmaceutical excipients Challenges in analytical methods to meet increasingly stringent targets How you can work with your excipient supplier to ensure high product quality